Standard-dose osimertinib for refractory leptomeningeal metastases in T790M-positive EGFR-mutant non-small cell lung cancer

被引：0

作者：

Shigeki Nanjo

Akito Hata

Chiyuki Okuda

Reiko Kaji

Hideaki Okada

Daisuke Tamura

Kei Irie

Hiroshi Okada

Shoji Fukushima

Nobuyuki Katakami

机构：

[1] Institute of Biomedical Research and Innovation Hospital,Division of Integrated Oncology

[2] 2-2,Department of Medical Oncology

[3] Minatojima-minamimachi,Department of Respiratory Medicine

[4] Chuo-ku,Department of Pharmacology

[5] Kobe 650-0047,Department of Pharmaceutics

[6] Japan,undefined

[7] Kobe Minimally Invasive Cancer Center,undefined

[8] Kobe 650-0046,undefined

[9] Japan,undefined

[10] Kobe University Hospital,undefined

[11] Kobe 650-0017,undefined

[12] Japan,undefined

[13] Institute of Biomedical Research and Innovation Hospital,undefined

[14] Kobe 650-0047,undefined

[15] Japan,undefined

[16] Faculty of Pharmaceutical Science,undefined

[17] Kobe Gakuin University,undefined

[18] Kobe 650-8586,undefined

[19] Japan,undefined

来源：

British Journal of Cancer | 2018年 / 118卷

关键词：

osimertinib; leptomeningeal metastases; T790M; cerebrospinal fluid;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：32 / 37

页数：5

共 50 条

[41] Osimertinib for Japanese patients with T790M-positive advanced non-small-cell lung cancer: A pooled subgroup analysis [J].

Hirashima, Tomonori ;

Satouchi, Miyako ;

Hida, Toyoaki ;

Nishio, Makoto ;

Kato, Terufumi ;

Sakai, Hiroshi ;

Imamura, Fumio ;

Kiura, Katsuyuki ;

Okamoto, Isamu ;

Kasahara, Kazuo ;

Uchida, Hirohiko ;

Vowler, Sarah L. ;

Mitsudomi, Tetsuya .

CANCER SCIENCE, 2019, 110 (09) :2884-2893

[42] Osimertinib Benefit in ctDNA T790M Positive, EGFR-Mutant NSCLC Patients [J].

Remon, Jordi ;

Caramella, Caroline ;

Joelet, Cecile ;

Lacroix, Ludovic ;

Lawson, Andrew ;

Smalley, Sarah ;

Howarth, Karen ;

Gale, Davina ;

Rosenfeld, Nitzan ;

Green, Emma ;

Plagnol, Vincent ;

Planchard, David ;

Bluthgen, Maria ;

Gazzah, Annas ;

Pannet, Chloe ;

Nicotra, Claudio ;

Soria, Jean-Charles ;

Besse, Benjamin .

JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) :S1254-S1255

[43] Osimertinib with Ramucirumab or Necitumumab in Advanced T790M-positive EGFR-Mutant NSCLC: Preliminary Ph1 Study Results [J].

Yu, H. ;

Planchard, D. ;

Yang, J. C. ;

Lee, K. H. ;

Garrido, P. ;

Park, K. ;

Kim, J. ;

Lee, D. H. ;

He, S. ;

Wolff, K. ;

Chao, B. ;

Paz-Ares, L. .

JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) :S1971-S1971

[44] Intracranial effect of osimertinib in relapsed EGFR-mutated T790M-positive and -negative non-small cell lung cancer patients: results from a phase II study [J].

Eide, Inger Johanne Zwicky ;

Grut, Harald ;

Helland, Aslaug ;

Ekman, Simon ;

Sorensen, Jens Benn ;

Hansen, Karin Holmskov ;

Gronberg, Bjorn Henning ;

Cicenas, Saulius ;

Koivunen, Jussi Pekka ;

Mellemgaard, Anders ;

Brustugun, Odd Terje .

ACTA ONCOLOGICA, 2021, 60 (12) :1565-1571

[45] Efficacy and Safety of Osimertinib in EGFR T790M-Positive Advanced NSCLC Patients with Brain Metastases (APOLLO Study) [J].

Xing, L. ;

Pan, Y. ;

Shi, Y. ;

Shu, Y. ;

Feng, J. ;

Li, W. ;

Cao, L. ;

Wang, L. ;

Gu, W. ;

Song, Y. ;

Yu, J. .

JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) :S592-S592

[46] A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy [J].

Park, S. ;

Lee, M-H ;

Seong, M. ;

Kim, S. T. ;

Kang, J-H ;

Cho, B. C. ;

Lee, K. H. ;

Cho, E. K. ;

Sun, J-M ;

Lee, S-H ;

Ahn, J. S. ;

Park, K. ;

Ahn, M-J .

ANNALS OF ONCOLOGY, 2020, 31 (10) :1397-1404

[47] Predicting osimertinib-treatment outcomes through EGFR mutant-fraction monitoring in the circulating tumor DNA of EGFR T790M-positive patients with non-small cell lung cancer (WJOG8815L) [J].

Sakai, Kazuko ;

Takahama, Takayuki ;

Shimokawa, Mototsugu ;

Azuma, Koichi ;

Takeda, Masayuki ;

Kato, Terufumi ;

Daga, Haruko ;

Okamoto, Isamu ;

Akamatsu, Hiroaki ;

Teraoka, Shunsuke ;

Ono, Akira ;

Ohira, Tatsuo ;

Yokoyama, Toshihide ;

Yamamoto, Nobuyuki ;

Nakagawa, Kazuhiko ;

Nishio, Kazuto .

MOLECULAR ONCOLOGY, 2021, 15 (01) :126-137

[48] Osimertinib for the treatment of epidermal growth factor receptor-mutated non-small cell lung cancer patients with leptomeningeal metastases and different T790M status [J].

Xu, Haiyan ;

Chen, Hengqi ;

Kong, Jianxin ;

Zhang, Ye ;

Liu, Shan ;

Yang, Guangjian ;

Yang, Lu ;

Wang, Yan .

ANNALS OF TRANSLATIONAL MEDICINE, 2021, 9 (11)

[49] Double-dose osimertinib combined with intrathecal injection of pemetrexed improves the efficacy of EGFR-mutant non-small cell lung cancer and leptomeningeal metastasis: case report and literature review [J].

Zhong, Wenjuan ;

Wu, Longqiu ;

Huang, Lixing ;

Wang, Jianfeng ;

Shi, Huaqiu ;

Wu, Shugui .

FRONTIERS IN ONCOLOGY, 2024, 14

[50] Safety and Efficacy of Osimertinib in Treating an EGFR-Mutant Lung Cancer Patient with a Germline EGFR T790M Mutation [J].

Ma, W. ;

Gong, J. ;

Shan, J. ;

Lewis, D. ;

Xiao, W. ;

Hung, J. ;

Moore, E. H. ;

Zhang, Y. ;

Mans, N. Z. ;

Welborn, J. ;

Lam, K. S. ;

Li, T. .

JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) :S1863-S1864

← 1 2 3 4 5 →